EP2197494A2 - Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion - Google Patents
Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesionInfo
- Publication number
- EP2197494A2 EP2197494A2 EP08801881A EP08801881A EP2197494A2 EP 2197494 A2 EP2197494 A2 EP 2197494A2 EP 08801881 A EP08801881 A EP 08801881A EP 08801881 A EP08801881 A EP 08801881A EP 2197494 A2 EP2197494 A2 EP 2197494A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- nanoparticle according
- heterocyclic compound
- selectin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08801881A EP2197494A2 (en) | 2007-09-05 | 2008-09-05 | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07017412A EP2033660A1 (en) | 2007-09-05 | 2007-09-05 | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
EP08801881A EP2197494A2 (en) | 2007-09-05 | 2008-09-05 | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
PCT/EP2008/007288 WO2009030492A2 (en) | 2007-09-05 | 2008-09-05 | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2197494A2 true EP2197494A2 (en) | 2010-06-23 |
Family
ID=39099812
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07017412A Withdrawn EP2033660A1 (en) | 2007-09-05 | 2007-09-05 | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
EP08801881A Withdrawn EP2197494A2 (en) | 2007-09-05 | 2008-09-05 | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07017412A Withdrawn EP2033660A1 (en) | 2007-09-05 | 2007-09-05 | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
Country Status (2)
Country | Link |
---|---|
EP (2) | EP2033660A1 (en) |
WO (1) | WO2009030492A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8295078B2 (en) | 2006-05-02 | 2012-10-23 | Micron Technology, Inc. | Semiconductor memory cell and array using punch-through to program and read same |
US8351266B2 (en) | 2009-04-27 | 2013-01-08 | Micron Technology, Inc. | Techniques for controlling a direct injection semiconductor memory device |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2123269A1 (en) * | 2008-05-21 | 2009-11-25 | Freie Universität Berlin | Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion |
DE102011101952A1 (en) * | 2011-05-18 | 2012-11-22 | Charité - Universitätsmedizin Berlin | Nanoparticles functionalized with dendritic polyglycerol sulfate |
AU2015327928A1 (en) | 2014-10-03 | 2017-05-04 | Nanotics, Llc | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
CN116763941A (en) * | 2015-06-30 | 2023-09-19 | 纳米提克斯有限责任公司 | Compositions and methods related to particle removal |
KR20180034619A (en) | 2015-07-29 | 2018-04-04 | 나노틱스 엘엘씨 | Module compositions for eradicating soluble biomolecules and related methods |
WO2017176762A1 (en) * | 2016-04-06 | 2017-10-12 | Nanotics, Llc | Particles comprising subparticles or nucleic acid scaffolds |
IL299915A (en) | 2017-01-04 | 2023-03-01 | Nanotics Llc | Methods for assembling scavenging particles |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0025414D0 (en) * | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
JP4429602B2 (en) * | 2000-11-24 | 2010-03-10 | ナノゲート アーゲー | Phase transfer of nanoparticles |
US20050003459A1 (en) * | 2002-01-30 | 2005-01-06 | Krutzik Siegfried Richard | Multi-purpose optical analysis disc for conducting assays and related methods for attaching capture agents |
WO2006037081A2 (en) * | 2004-09-28 | 2006-04-06 | The Regents Of The University Of California | Nanoparticle radiosensitizers |
-
2007
- 2007-09-05 EP EP07017412A patent/EP2033660A1/en not_active Withdrawn
-
2008
- 2008-09-05 WO PCT/EP2008/007288 patent/WO2009030492A2/en active Application Filing
- 2008-09-05 EP EP08801881A patent/EP2197494A2/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2009030492A2 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8295078B2 (en) | 2006-05-02 | 2012-10-23 | Micron Technology, Inc. | Semiconductor memory cell and array using punch-through to program and read same |
US8351266B2 (en) | 2009-04-27 | 2013-01-08 | Micron Technology, Inc. | Techniques for controlling a direct injection semiconductor memory device |
Also Published As
Publication number | Publication date |
---|---|
WO2009030492A3 (en) | 2009-09-03 |
EP2033660A1 (en) | 2009-03-11 |
WO2009030492A2 (en) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009030492A2 (en) | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion | |
CN103864677B (en) | Thioacetic acid salt compound, compoistion and method of use | |
US9242003B2 (en) | Surface-modified heavy metal nanoparticles, compositions and uses thereof | |
JP2013527157A (en) | Prodrug composition, prodrug nanoparticles and methods of use thereof | |
JP2009501791A (en) | Method for binding therapeutic compounds to cell targeting devices via metal complexes | |
Roskamp et al. | Multivalent interaction and selectivities in selectin binding of functionalized gold colloids decorated with carbohydrate mimetics | |
CN102939279A (en) | Phenylthioacetate compounds, compositions and methods of use | |
Morgese et al. | Ultrastable suspensions of polyoxazoline-functionalized ZnO single nanocrystals | |
US20160251320A1 (en) | Compounds | |
Assali et al. | Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity | |
JP2022552757A (en) | Camptothecin class drugs and their antibody conjugates | |
US20120269903A1 (en) | Novel mannopyranoside derivatives with anticancer activity | |
CN106083925B (en) | Diphosphonic acid compound and preparation method and application thereof | |
Champagne et al. | Synthesis and Unprecedented Complexation Properties of β-Cyclodextrin-Based Ligand for Lanthanide Ions | |
CN102089276A (en) | Modulation of enzymatic structure, activity, and/or expression level | |
ES2903387T3 (en) | Biocompatible magnetic materials | |
Sarmento et al. | Biomedical applications of functionalized nanomaterials: concepts, development and clinical translation | |
EP2123269A1 (en) | Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion | |
CN109152750A (en) | Combination treatment for proliferative diseases | |
CN108976318A (en) | Mono- 6-(biotin amido group) -6- deoxidation-beta-cyclodextrin and its preparation method and application | |
JP2011515330A (en) | Improved antitumor treatment | |
CN102952207B (en) | Preparation method and application of 6-(1-methyl-beta-carboline-3-carboxylic acetyl)-6-deoxy-beta-cyclodextrin and supramolecular inclusion complex thereof with adriamycin | |
Das et al. | Enhanced potency of nucleotide− dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition | |
CN109761915B (en) | 5-fluorouracil ester-forming prodrugs targeting the MCT1 transporter | |
KR20190075389A (en) | Pharmaceutical composition comprising a nanostructure carrying an anticancer drug for treating liver cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100331 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: YEKTA, SHAHLA Inventor name: ENDERS, SVEN Inventor name: ROSKAMP, MEIKE Inventor name: SCHLECHT, SABINE Inventor name: DERNEDDE, JENS Inventor name: REISSIG, HANS-ULRICH |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20140319 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140401 |